Watchlist

Watchlist
ANI Pharmaceuticals, Inc. (ANIP)
ANI Pharmaceuticals, Inc. (ANIP)
ANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q1 2018 Results - Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q1 2018 Earnings Conference Call May 08, 2018 10:30 AM ET Executives Arthur Przybyl - CEO, President and Director Stephen Carey - CFO and VP of Finance Analysts Dewey Steadman - Canaccord Elliot Wilbur - Raymond James Presentation Ope…
ANI Pharmaceuticals beats by $0.04, misses on revenue
ANI Pharmaceuticals (NASDAQ: ANIP ): Q1 EPS of $1.32 beats by $0.04 . Revenue of $46.5M (+26.9% Y/Y) misses by $3.43M . Press Release More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance
BAUDETTE, Minn. , May 8, 2018 /PRNewswire/ -- For the first quarter 2018: Net revenues of $46.5 million , an increase of 27% as compared to the same period in 2017 GAAP net income of $2.3 million and diluted GAAP earnings per share of $0.19 Adjusted non-GAAP EBITDA …
Notable earnings before Tuesday's open
ACM , AES , AFI , ANIP , AQUA , ARMK , ATHM , ATRS , BLD , BMCH , BR , COHU , CORE , CRCM , CROX , CWH , DEA , DF , DISCA , DISH , DNR , DQ , EGN , ENDP , EPZM , ETM , EXPD , FI , FRTA , FSS , GCP , GTN , HAE , HAIN , HSIC , HUD , ICPT , IT , JD , JEC…
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
BAUDETTE, Minn. , May 7, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has completed the acquisition of a portfolio of six generic products, related manufacturing and supply agreements, and equipment and technical know-how from Amneal P…
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results
BAUDETTE, Minn. , May 1, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2018 financial results on Tuesday, May 8, 2018 , before the opening of the U.S. financial markets. The earnings press release…
Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up
Analysis focus: Akorn Akorn Therapeutics (AKRX) has gained considerably on hopes that it will, after all, reach a buyout deal with Fresenius (FMS). The $4.75bn deal has been going through some rough patch after Fresenius pulled out of the deal last week. Trouble began in late February wh…
ANI Pharmaceuticals buying assets from Amneal, Impax
ANI Pharmaceuticals (NASDAQ: ANIP ) has signed definitive deals to acquire generic products and assets from Amneal Pharmaceuticals and Impax Laboratories (NASDAQ: IPXL ) for cash. More news on: ANI Pharmaceuticals, Inc., Impax Laboratories, Inc., Healthcare stocks news, Merger & acqu…
Amneal And Impax Receive FTC Clearance For Business Combination
BRIDGEWATER, N.J. , April 27, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Federal Trade Commission (FTC) has cleared the Amneal and Impax business combination, subject to Amneal and Impax's agreement to…
ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/Impax
BAUDETTE, Minn. , April 27, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has signed definitive agreements to acquire a portfolio of generic products and other assets from Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc. (NASDAQ…
ANI Pharmaceuticals, Inc. (ANIP)